Published by the IP Litigation Group
e-Alert
McCarthy Tétrault 2013
July
17



Merck Awarded More Than $180 Million Against Apotex for Infringement of Lovastatin Patent
On July 16, 2013, the Federal Court released its Public Judgment and Reasons for Judgment in Merck & Co. Inc. and Merck Canada Inc. v. Apotex Inc. et al. [2013] FC 751 awarding Merck a total of over $180 million dollars in damages and prejudgment interest for Apotex’s infringement of Merck’s lovastatin patent. In addition to the significant damage award, the decision is important for a number of legal and strategic reasons ...
FULL STORY